Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Istradefylline to reduce microglial activation in progressive multiple sclerosis
2024-517336-21-00Phase 2Authorised
- Sponsor
- University of Turku
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) comparing Istradefylline arm with Placebo arm (2 arms). Planned start Nov 2024; status: authorised.
02
Drugs
Istradefylline
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-517336-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517336-21-00.